A pioneering medtech company in cancer diagnostics
SciBase AB is a Swedish medtech company founded in Stockholm in 1998. SciBase has developed a unique point of care device for the accurate detection of malignant melanoma (skin cancer), which significantly increases the physician’s ability to detect and monitor skin tissue alteration.
Skin cancer is the most common and one of the fastest growing form of cancer in the world, and malignant melanoma is the most dangerous form of skin cancer with a high mortality rate if not detected in time. Today, some 50-60 million annual examinations for malignant melanoma are performed, of which 5-6 million lead to excisions. Of these, some 93-97 percent are shown to be benign. With this product, the number of unnecessary interventions can be reduced by up to 40 percent.
Emerged from more than 20 years of academic research
The SciBase method is based on a technology called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. It has emerged from more than 20 years of academic research at Karolinska Institutet Stockholm. Through a crooked path of theoretical philosophy, applied physics and sensing technologies, Stig Ollmar, researcher and founder of SciBase, and his research colleagues established the foundation of what today is the SciBase method at Karolinska Institutet Stockholm in the early 1990s. Further research was conducted, with great improvements of the method as a result, which led to SciBase being founded in 1998. Since then, further research, a pilot study, and a number of clinical studies has improved and proved the benefits of the method.
A strong and global IP portfolio
Our Managing Partner and Head of Patent Department, Mathias Loqvist has been working with SciBase since 2002. Through a close cooperation we have assisted SciBase with patent services ranging from drafting and prosecution of their patent applications to strategical advice in connection with IPO and Due Diligence as preparation for investments. Our work has resulted in a global and comprehensive patent portfolio. We are also handling SciBase’s trademarks worldwide, acting as the lead agency and coordinating all work globally.
Improving health care for patients worldwide
Three consecutive and comprehensive clinical studies, with excellent clinical results, have been performed to date for the SciBase method. A successful pivotal study was finalized in 2012 including 1,951 patients and 2,416 lesions at 22 sites in Europe and US.
Today, SciBase is a listed company with a product on the market, approved for sales in Europe, Australia and USA.